(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University...
Stats | |
---|---|
本日の出来高 | 77 054 |
平均出来高 | 0 |
時価総額 | 1.43M |
EPS | $-1.680 ( Q1 | 2024-05-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.00100 (9.80%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Feldmann Marc | Buy | 135 377 | Common Stock |
2023-12-15 | Feldmann Marc | Sell | 25 000 | Common Stock |
2023-12-15 | Woody James N. | Buy | 25 000 | Common Stock |
2023-09-04 | Feldmann Marc | Buy | 15 000 | Non-Qualified Stock Option (right to buy) |
2023-09-04 | Ray Russell T | Buy | 21 455 | Common Stock |
INSIDER POWER |
---|
91.31 |
Last 31 transactions |
Buy: 766 364 | Sell: 25 000 |
CannBioRx Life Sciences 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-105 675 (0.00 %) |
EPS: | $-52.60 |
FY | 2023 |
収益: | $0 |
総利益: | $-105 675 (0.00 %) |
EPS: | $-52.60 |
FY | 2022 |
収益: | $0 |
総利益: | $-109 004 (0.00 %) |
EPS: | $-387.19 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CannBioRx Life Sciences
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。